BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

WhitePaper

Biotech Failures 2026: What Did Not Happen in APAC Biopharma

Approvals get counted, deals get ranked, listings get priced. The other half of the year, the programmes that stopped, the applications that came back, the...

October 02, 2026 | Analysis

APAC Biotech IPOs of 2026: Who Listed, What It Raised, Where It Trades Now

How this list was built Scope. Every biotech initial public offering with a first trading day between 1 January and 24 September 2026 on five venu...

September 29, 2026 | Analysis

The 10 Deals That Defined APAC Biopharma in 2026

The biggest pharma deals of 2026 with an Asia-Pacific principal are easy to list and hard to rank. The ten on this page carry more than US$70 billion in he...

September 25, 2026 | Analysis

Every First Approval in APAC, 2026: The Full List

Asia-Pacific’s New Drug Boom: 99 Approvals, 20 World Firsts Somewhere in the second week of January, a BeOne Medicines BCL2 inhibitor called sonroto...

September 23, 2026 | Analysis

Why 10,000 Koreans a Year Still Fly Abroad for Stem Cell Treatment

METHOD IN BRIEF This feature expands entry 21 of our year-end count, 2026 in 26 Numbers. Every figure is cited to a regulator publication, offi...

September 21, 2026 | Analysis

2026 in 26 Numbers: The APAC Biopharma Year, Counted

METHOD IN BRIEF A number qualifies for this list only if it is sourced to a company disclosure, regulator publication, exchange filing or peer-...

September 21, 2026 | Analysis

The Arbitrage Triangle

METHOD IN BRIEF Flow estimates come from published government statistics and press reporting of official material; no authority in the region publishes in...

September 09, 2026 | Analysis

Where the Longevity Money Actually Goes

METHOD IN BRIEF Window: 1 January to 31 August 2026 for round-level claims, with full-year 2024 and 2025 figures for context. Attribution follows scientif...

September 07, 2026 | Analysis

Nobody Is the Payer

A gerotherapeutic that delays five diseases by three years each would produce savings across five budget lines over thirty years, and a cost that lands in ...

September 04, 2026 | Analysis

Food, Drug, or Neither

Yesterday was the deadline. Japan's Consumer Affairs Agency has stated that the revised labelling provisions and mandatory Good Manufacturing Practice sta...

September 03, 2026 | Analysis

Making a Drug People Take for Twenty Years

METHOD IN BRIEF Cost-of-goods figures in this article are reconstructions, not disclosures. No company supplied a cost-of-goods figure and none is...

September 01, 2026 | News

The Accidental Gerotherapeutic

METHOD IN BRIEF Outcome evidence in this article is taken from published trial results and approved label language only. No efficacy or outcome claim is s...

August 31, 2026 | Analysis

The Biological Age Business

On coming 4th September at six in the evening Singapore time, a public consultation will close. It opened on 7 August, it is still open as this is publishe...

August 27, 2026 | Analysis

6 Radiopharmaceutical Programmes and Sites to Watch in APAC

Radioligand therapy is the one modality a region cannot buy its way into late. A vial of lutetium-177 loses half its therapeutic activity in roughly six an...

August 18, 2026 | Analysis

Stay Connected